Contact
Biography
I am an academic with research expertise in physiologically based pharmacokinetic (PBPK). I aspire to mentor and inspire the next generations of scientists.
I completed my BPharm degree in Pharmacy from the University of Lagos, Nigeria, and proceeded to gain clinical pharmacy experience as a pharmacist at the Chevron Nigeria Limited Hospital in Lagos and Reddington Multispecialist Hospital in Lagos for about 3 years.
I have an MSc. clinical pharmacy degree from the University of Strathclyde, Glasgow and I did my MSc project in the area of pharmacokinetics under the supervision of Dr Alison Thomson.
I have a PhD degree in physiologically based pharmacokinetics from Aston University which was obtained under the supervision of Dr Raj S.K Badhan and Prof Michael Coleman. My research involved the development of physiologically based pharmacokinetic models for antimalarial drugs used in special populations and was aimed at assessment of the pharmacokinetics of antimalarials in these population groups with the focus of understanding the pharmacokinetics of antimalarials and optimisation of antimalarial medication therapy.
I joined the University of Nottingham in 2019 as an Assistant Professor in Pharmacology.
Expertise Summary
Pharmacokinetics, PBPK modelling in paediatrics and pregnant women, pharmacometrics, clinical pharmacokinetics
Teaching Summary
I am passionate about research inspired teaching excellence. I am currently a fellow of the HEA and hope to climb up the ranks in the future.
I am passionate about utilising current technologies to enhance students learning experience and facilitating learning in ways that promotes students engagement with the contents being learnt.
Research Summary
My current research involves integrating in-vitro pharmacokinetics and PBPK modelling techniques to understand and optimise the pharmacokinetics profiles of several drug compounds.
Future Research
In the future, I hope to lead research that answers key drug development questions relating to the pharmacokinetic behavior of drug candidates much earlier on in the drug development process using an integration of in vitro and in silico techniques. The approach will be aimed at reducing the likelihood of PK-related attritions during drug development and predicting the pharmacokinetic and toxicological profiles of drug candidates in humans before they enter Ph1 clinical trials.